<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03570931</url>
  </required_header>
  <id_info>
    <org_study_id>RT001-008</org_study_id>
    <nct_id>NCT03570931</nct_id>
  </id_info>
  <brief_title>A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy</brief_title>
  <official_title>A Prospective Open-label Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retrotope, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Retrotope, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of RT001 in patients with&#xD;
      Infantile Neuroaxonal Dystrophy (INAD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm open-label study with a structured observation of INAD patients treated&#xD;
      with RT001. Enrolled subjects will undergo observation and testing to determine the effect of&#xD;
      RT001 treatment. Fifteen to twenty eligible subjects will be treated with RT001 for long-term&#xD;
      evaluation of efficacy, safety, tolerability, and pharmacokinetics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 5, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Actual">August 9, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm open-label study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Ashworth Spasticity Scale</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in the Modified Ashworth spasticity scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>INAD Progression Composite</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in an INAD composite score to assess the overall treatment effect on the most progressive aspects of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival Time</measure>
    <time_frame>All available data</time_frame>
    <description>Progression free survival time (mortality or pneumonia)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Modified Infantile Neuroaxonal Dystrophy Rating Scale (mINAD-RS24)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in score from baseline derived from a structured pediatric neurological development exam tailored for INAD, involving elements of activities of daily living and vital functions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Parental Rating Scale (mPRS22)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in score from baseline from a parental rating scale tailored for INAD, involving elements of activities of daily living and vital functions</description>
  </other_outcome>
  <other_outcome>
    <measure>Original Infantile Neuroaxonal Dystrophy Rating Scale (INAD-RS40)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in score from baseline derived from a structured pediatric neurological development exam tailored for INAD, involving elements of activities of daily living and vital functions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Original Parental Rating Scale (mPRS33)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in score from baseline from a parental rating scale tailored for INAD, involving elements of activities of daily living and vital functions</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>The incidence of treatment-emergent adverse events will be presented by severity and relationship to study drug.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Infantile Neuroaxonal Dystrophy</condition>
  <arm_group>
    <arm_group_label>RT001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RT001, oral, 3.84 g/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RT001</intervention_name>
    <description>RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 960 mg of RT001.</description>
    <arm_group_label>RT001</arm_group_label>
    <other_name>Deuterated linoleic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female 18 months to 10 years of age&#xD;
&#xD;
          2. Medical history consistent with the symptoms of classic INAD (onset of symptoms&#xD;
             between the ages of 6 months and 3 years)&#xD;
&#xD;
          3. Homozygous for PLA2G6 deficiency (variant alleles may be mixed heterozygotes)&#xD;
&#xD;
          4. Must have impairment in at least 2 of the assessed categories at baseline&#xD;
&#xD;
          5. Signed informed consent form (ICF) prior to entry into the study&#xD;
&#xD;
          6. Able to provide the necessary blood samples&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received treatment with other experimental therapies within the last 30 days prior to&#xD;
             the first dose&#xD;
&#xD;
          2. Requiring mechanical ventilation, other than positive air pressure support primarily&#xD;
             for mitigation of sleep apnea.&#xD;
&#xD;
          3. Have a life expectancy of less than one year&#xD;
&#xD;
          4. Diagnosis of atypical NAD (ANAD)&#xD;
&#xD;
          5. Unwilling or unable to comply with the requirements of this protocol, including the&#xD;
             presence of any condition (physical, mental, or social) that is likely to affect the&#xD;
             subject's ability to return for visits as scheduled&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Milner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco, Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobs Levy Genomics and Research Program</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>INAD</keyword>
  <keyword>Infantile Neuroaxonal Dystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroaxonal Dystrophies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

